The World Market for Cancer Diagnostics, 2014-2019, 6th Edition (Histology [ISH, IHC, HPV, Pap], Flow Cytometry, PSA, CEA, Liquid Biopsy, FOB and Other Rapid, Image Cytometry, Sequencing, Digital Pathology, Molecular Assays)

 
   Single User - $1,995
   Site License (one location, 10 users) - $2,500
   Corporate License - $3,995



Loading...
Published Sep 11, 2015 | 861 Pages | Pub ID: KLI5686737

The World Market for Cancer Diagnostics, 2014-2019, 6th Edition (Histology [ISH, IHC, HPV, Pap], Flow Cytometry, PSA, CEA, Liquid Biopsy, FOB and Other Rapid, Image Cytometry, Sequencing, Digital Pathology, Molecular Assays)

Cancer testing is maturing from personalized medicine to precision medicine, where protein and molecular biomarkers are essential for precise diagnosis, therapy selection, therapy monitoring and early detection of cancer recurrence.  The World Market for Cancer Diagnostics, 6th Edition., as well as relevant industry merger data provided by Kalorama Information, provides authoritative and complete analysis of the cancer testing industry, with expert market sizing and opportunity assessment.  

Segment markets for cancer testing are comprehensively covered in Kalorama Information's World Market for Cancer Diagnostics, 6th. Edition.  The report contains detailed market data on the following IVD segments for their use in cancer diagnostics:

  • IVD Market for Cancer Tests
  • Service Test Market
  • in situ hybridization (ISH)
  • Immunohistochemistry (IHC)
  • FOB and Other Rapid Tests
  • PSA, CEA and Other Markers
  • Flow Cytometry
  • Pap and HPV Testing
  • Molecular Oncology Assays
  • Tissue Microrrays
  • Methylated DNA
  • Circulating Tumor Cells
  • Next-Generation Sequencing Technologies
  • Tissue Function Tests
  • Companion Testing, CDX Products and Deals

The Race for Prevention Supports a Market for Innovative Diagnostic Tools 

Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As this report goes to print a number of significant developments are taking place in cancer follow up. New imaging tools, bioinformatics, sequencing technologies, improved histological tests are among the trends discussed in this multifaceted report.  The importance of this industry is seen in the flurry of investments and financing arrangements made and the number of partnerships and purchases/mergers where one or both companies are involved in cancer diagnostics.  This report contains
 
  • Investments and Financing Agreements For Cancer Diagnostics Companies
  • Selected Agreements Between Cancer Diagnostic Companies
  • Selected Agreements Between Cancer Diagnostic Companies and Other Diagnostic Companies 
  • Selected Agreements Between Cancer Diagnostic Companies and Pharmaceutical or Biopharmaceutical Companies
  • Selected Cancer Diagnostic Company Agreements with Academic or Other Non-Profit Organizations
  • Selected Acquisitions of Cancer Diagnostic Companies

Complete Market and Trend Analysis 

In five previous editions. Kalorama has defined the oncology testing market, based on primary research of the market with particular attention to important market trends.  These trends are more important to understand than today's numbers.  Market analysis in this report covers world markets for in vitro cancer diagnostics, however the reader will find a bias toward the developed areas of the globe -- N. America, Japan and Western Europe. However cancer is a growing global problem and where possible the report covers cancer testing in the more industrialized developing countries of Latin America and Asia Pacific. 

The phenomenon of test personalization comes under many guises as pharmacogenomic, pharmacogenetic, companion tests, and represents one of the fastest growing segments of the market for cancer tests. It has emerged fully from research into clinical practice. Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. Some personalized cancer tests are CE Marked and FDA-cleared and many more are in development. More and more laboratories offer complex panels of tests that help physicians evaluate disease risk and make therapeutic decisions. Government and private healthcare payers have recognized the value of new molecular tools and are agreeing to pay for them. 

Unparalleled Review of Cancer Testing Competitors: Top Tier IVD Companies And Specialist Companies 

This report is written from the point of view of diagnostic modalities for the detection and management of cancer and in particular solid tumors. The technology to detect cancers of the blood - lymphomas, myelomas and leukemia - is mature and well established. The routine complete blood count screens for blood cell abnormalities and is followed by bone marrow analysis and flow cytometric studies of the blood cell surface markers. These to arrive at a more specific diagnosis. As such this report does not discuss area of hematological cancer diagnosis in great detail. 

The emphasis is on in vitro diagnostic tests, however a discussion of the role of diagnostics in cancer management, must include in vitro and in vivo tests. The two are inextricably linked. The same cell markers used in flow cytometry and antibodies used for immunoassays to detect elements of the immunity process are used as vectors for imaging agents to detect tumors and to monitor the extent of cancer metastasis. 

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in several sections, including the following companies:

  • M Genomics Ltd.
  • 20/20 GeneSystems, Inc.
  • AB SCIEX
  • Abbott Laboratories
  •  Abcodia Ltd.
  • Abingdon Health Ltd
  • Abnova Corporation
  • ACT Genomics Co., Ltd.
  • Adaptive Biotechnologies Corporation
  • Admera Health (a GENEWIZ company)
  • Advanced Cell Diagnostics
  • Affymetrix, Inc.
  • Agena Bioscience Inc.
  • Agendia NV
  • Agilent Technologies Inc.
  • Alere Inc.
  • Ambry Genetics Corp.
  • Amoy Diagnostics Co., Ltd.
  • ANGLE plc
  • ApoCell, Inc.
  • Applied Proteomics, Inc.
  • Applied Spectral Imaging, Inc.
  • Arbor Vita Corporation
  • ARKRAY, Inc.
  • ARUP Laboratories
  • Astra Biotech GmbH
  • Asuragen, Inc.
  • AsymmetRx Medical, Inc.
  • Atossa Genetics Inc.
  •  AutoGenomics, Inc
  • Avant Diagnostics, Inc. (formerly Arrayit Diagnostics Inc.)
  • Axela, Inc
  • AXO Science
  • Beckman Coulter, Inc. (subsidiary of Danaher Corporation)
  • Becton, Dickinson and Company (BD)
  •  BGI-Shenzhen
  • The Binding Site Group Ltd.
  • Biocare Medical, LLC
  • Biocartis SA
  • Biocept, Inc.
  •  Biodesix, Inc.
  • BioFluidica
  • BioGenex
  • Biological Dynamics Inc.
  • BioMarker Strategies
  • bioMérieux SA
  • BioMosaics
  • Bio-Rad Laboratories, Inc.
  • Bio-Reference Laboratories, Inc. (BRLI)
  • BioSystems
  • bioTheranostics (a bioMérieux company)
  • Biotype Diagnostic GmbH
  • BioView Ltd
  • Boditech Med Inc.
  •  Cancer Genetics, Inc.
  •  Canopus Bioscience Ltd.
  • Caprion, Inc.
  • Caris Life Sciences
  • Castle Biosciences, Inc.
  • CDx Diagnostics
  • Celerus Diagnostics, Inc.
  • Cellmid Ltd.
  • Centogene AG
  • Cepheid
  •  Cernostics
  • Cirdan Imaging Ltd
  • Clarient Diagnostic Services, Inc. (a GE Healthcare company)
  • Clearbridge BioMedics Pte Ltd
  • Color Genomics, Inc.
  • Counsyl, Inc.
  • Cube Dx GmbH
  • Cynvenio Biosystems, Inc.
  • CytoTest Inc.
  • Dako A/S (an Agilent company)
  • Danaher Corporation
  • DermTech, Inc.
  • DiaCarta, Inc.
  • DiaSorin S.p.A.
  • DiaTech Oncology
  • EDP Biotech Corporation
  • Eiken Chemical Co., Ltd.
  •  EntroGen, Inc.
  • Enzo Biochem, Inc
  • Enzo Life Sciences, Inc.
  • Enzo Clinical Labs, Inc.
  • Epic Sciences, Inc.
  • Epigenomics AG
  • Eutropics Pharmaceuticals
  • Exact Sciences Corporation
  •  Exosome Diagnostics, Inc.
  • Fluxion Biosciences, Inc.
  • Foundation Medicine, Inc.
  • Fujirebio Inc.
  • Fujirebio Diagnositics, Inc.
  •  GE Healthcare
  • Genalyte, Inc.
  • GeneCentric Diagnostics, Inc.
  • Genection, Inc. (an Invivoscribe company)
  • GeneDx
  • GeneNews Limited
  • Genetic Technologies Limited / Phenogen Sciences, Inc. (U.S. division)
  • GenomeDx Biosciences
  • Genomica S.A.U.
  • Genomic Health, Inc.
  •  Genomic Vision
  • Genoptix (a Novartis company)
  • GenPath / GenPath Women’s Health and GenPath Oncology
  • Guardant Health, Inc.
  • HalioDx
  • Healgen Scientific LLC
  • Helomics Corporation
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  •  Human Longevity, Inc.
  • Icellate AB
  • Ikonisys, Inc.
  • Illumina, Inc.
  • ImCare BioTech
  • Immunovia AB
  • IncellDx, Inc.
  • Inform Genomics, Inc.
  • Financings
  • Other Agreements
  • Inivata Ltd.
  • Innovations Exchange Pte Ltd (INEX)
  • Insight Genetics, Inc.
  • IntegraGen SA
  • Integrated Diagnostics, Inc.
  • Invitae Corporation
  •  Invivoscribe Technologies, Inc.
  • Iris BioTechnologies Inc.
  • Janssen Diagnostics / Janssen Diagnostics BVBA
  • Janssen Diagnostics, LLC
  • Laboratory Corporation of America (LabCorp) / Integrated Genetics
  •  Leica Biosystems Inc. (a Danaher company)
  • Leica Microsystems (a Danaher company)
  • Lifecode, Inc.
  • MagArray, Inc.
  • Martell Diagnostic Laboratories, Inc.
  • Matrix-Bio, Inc.
  • Mayo Medical Laboratories and Mayo Clinic
  • Medical & Biological Laboratories Co., Ltd. (MBL)
  • MBL International Corporation
  •  MDxHealth SA
  • Metamark Genetics, Inc.
  • MetaStat, Inc.
  • MolecularMD Corporation
  • Multiplicom NV
  • Myriad Genetics, Inc.
  • Myriad RBM, Inc.
  • NanoIVD, Inc.
  • NanoString Technologies, Inc.
  • NeoGenomics, Inc. / NeoGenomics Laboratories
  •  NewGene Ltd.
  • New Oncology AG
  • Nuclea Biotechnologies, Inc.
  • Ohmx Corporation
  • Omnyx
  • Oncimmune Ltd.
  • Oncimmune (USA) LLC (acquired by HDL Inc.)
  • Health Diagnostic Laboratory, Inc.
  • OncoCyte Corporation
  • OncoDNA SA
  • OncoHealth Corp.
  • Oncolab, Inc.
  • Oncolys BioPharma Inc.
  • Oncompass GmbH
  • Onconome, Inc.
  • OncoPlex Diagnostics (OncoPlexDx)
  • Oncospire Genomics
  • OPKO Health, Inc. / OPKO Diagnostics
  •  Orion Genomics
  • Ortho-Clinical Diagnostics
  •  OvaGene Oncology Inc.
  • Oxford Cancer Biomarkers Ltd.
  • Oxford Gene Technology
  • Pacific Edge Limited
  • Pathway Genomics Corporation
  • Personal Genome Diagnostics, Inc.
  • PGXL Laboratories
  • Phenomenome Discoveries Inc.
  • Polymedco, Inc.
  • PreTect AS
  • PrognosDx Health, Inc.
  • Provista Diagnostics, Inc.
  • QIAGEN N.V.
  • QuanDx
  • Quanterix Corporation
  • QuantuMDx Group
  • Quest Diagnostics
  •  RainDance Technologies, Inc.
  • Randox Laboratories Ltd
  • Rarecells SAS
  • Response Genetics, Inc.
  •  Rheonix, Inc.
  • RiboMed Biotechnologies, Inc.
  • Roche
  •  Rosetta Genomics Ltd.
  •  ScheBo-Biotech AG
  • ScreenCell
  • Sequenom, Inc.
  •  Siemens Healthcare Diagnostics
  • Symbiodx
  • Sysmex Corporation
  • TeloVISION, LLC
  • Theranostics Health Inc.
  • Thermo Fisher Scientific, Inc.
  • Tosoh Corporation
  • Tosoh Bioscience, Inc.
  • Transgenomic, Inc.
  • TrimGen Corporation
  • TrovaGene, Inc.
  •  Vela Diagnostics
  • Ventana Medical Systems, Inc. (member of the Roche Group)
  • Veracyte, Inc.
  •  Wako Diagnostics
  • Wako Pure Chemical Industries, Ltd.,
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.